Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.11.21	Xencor : Early-stage Studies On Vudalimab Suggest PD-1 And CTLA-4 Promise In Prostate Cancer (RTTNews)
07.11.21	Ausblick: Xencor veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
02.08.21	Ausblick: Xencor präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
27.05.21	Xencor to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
27.05.21	GlaxoSmithKline-Vir COVID-19 Antibody Drug Granted EUA In U.S. (RTTNews)
27.05.21	Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 (Businesswire)
25.05.21	Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19 - Quick Facts (RTTNews)
25.05.21	Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19 (Businesswire)
12.05.21	Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference (Businesswire)
05.05.21	Xencor Reports First Quarter 2021 Financial Results (Businesswire)
28.04.21	Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases (Businesswire)
28.04.21	Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021 (Businesswire)
10.04.21	Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021 (Businesswire)
11.03.21	Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021 (Businesswire)
03.03.21	Xencor to Present at the Barclays Global Healthcare Conference (Businesswire)
25.02.21	Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics (Businesswire)
23.02.21	Xencor Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
21.02.21	Ausblick: Xencor zieht Bilanz zum jüngsten Jahresviertel (finanzen.net)
16.02.21	Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021 (Businesswire)
04.02.21	Xencor to Present at Upcoming Investor Conferences (Businesswire)
06.01.21	Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer (Businesswire)
07.12.20	Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer (Businesswire)
06.12.20	Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting (Businesswire)
12.11.20	Xencor to Present at Upcoming Investor Conferences (Businesswire)
11.11.20	Xencor, MorphoSys And Incyte Ink Collaboration Deal (RTTNews)
11.11.20	Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab (Businesswire)
09.11.20	Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting (Businesswire)
09.11.20	Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting (Businesswire)
05.11.20	Xencor Reports Third Quarter 2020 Financial Results (Businesswire)
04.11.20	Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting (Businesswire)
29.10.20	Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020 (Businesswire)
14.10.20	Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting (Businesswire)
02.10.20	Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium (Businesswire)
09.09.20	Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference (Businesswire)
09.09.20	Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium (Businesswire)
03.09.20	Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates (Businesswire)
05.08.20	Xencor to Present at Upcoming Investor Conferences (Businesswire)
04.08.20	Xencor Reports Second Quarter 2020 Financial Results (Businesswire)
03.08.20	Ausblick: Xencor zieht Bilanz zum abgelaufenen Quartal (finanzen.net)
01.08.20	Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States (Businesswire)
28.07.20	Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020 (Businesswire)
08.07.20	Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies (Businesswire)
22.06.20	Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II (Businesswire)
26.05.20	Xencor to Present at Upcoming Investor Conferences (Businesswire)
15.05.20	Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II (Businesswire)
13.05.20	Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors (Businesswire)
13.05.20	Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference (Businesswire)
07.05.20	Xencor Reports First Quarter 2020 Financial Results (Businesswire)
07.05.20	Ausblick: Xencor präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
30.04.20	Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten